Laurel Officer, Carmel Armon, Paul Barkhaus, Morgan Beauchamp, Michael Benatar, Tulio E. Bertorini, Robert Bowser, Mark B. Bromberg, Andrew Brown, O. Carbunar, Gregory T. Carter, J. Crayle, Keelie Denson, Eva Feldman, Timothy R Fullam, Terry Heiman-Patterson, Carlayne Jackson, Sartaj Jhooty, Danelle Levinson, Xiaoyan Li, Alexandra Linares, Elise Mallon, Javier Mascías Cadavid, C. Mcdermott, Tasnim Mushannen, L. Ostrow, Ronak Patel, Gary L. Pattee, Dylan Ratner, Yuyao Sun, J. Sladky, Paul Wicks, Richard Bedlack
{"title":"ALSUntangled #75: Portable neuromodulation stimulator therapy.","authors":"Laurel Officer, Carmel Armon, Paul Barkhaus, Morgan Beauchamp, Michael Benatar, Tulio E. Bertorini, Robert Bowser, Mark B. Bromberg, Andrew Brown, O. Carbunar, Gregory T. Carter, J. Crayle, Keelie Denson, Eva Feldman, Timothy R Fullam, Terry Heiman-Patterson, Carlayne Jackson, Sartaj Jhooty, Danelle Levinson, Xiaoyan Li, Alexandra Linares, Elise Mallon, Javier Mascías Cadavid, C. Mcdermott, Tasnim Mushannen, L. Ostrow, Ronak Patel, Gary L. Pattee, Dylan Ratner, Yuyao Sun, J. Sladky, Paul Wicks, Richard Bedlack","doi":"10.1080/21678421.2024.2346825","DOIUrl":null,"url":null,"abstract":"Spurred by patient interest, ALSUntangled herein examines the potential of the Portable Neuromodulation Stimulator (PoNS™) in treating amyotrophic lateral sclerosis (ALS). The PoNS™ device, FDA-approved for the treatment of gait deficits in adult patients with multiple sclerosis, utilizes translingual neurostimulation to stimulate trigeminal and facial nerves via the tongue, aiming to induce neuroplastic changes. While there are early, promising data for PoNS treatment to improve gait and balance in multiple sclerosis, stroke, and traumatic brain injury, no pre-clinical or clinical studies have been performed in ALS. Although reasonably safe, high costs and prescription requirements will limit PoNS accessibility. At this time, due to the lack of ALS-relevant data, we cannot endorse the use of PoNS as an ALS treatment.","PeriodicalId":72184,"journal":{"name":"Amyotrophic lateral sclerosis & frontotemporal degeneration","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Amyotrophic lateral sclerosis & frontotemporal degeneration","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/21678421.2024.2346825","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Spurred by patient interest, ALSUntangled herein examines the potential of the Portable Neuromodulation Stimulator (PoNS™) in treating amyotrophic lateral sclerosis (ALS). The PoNS™ device, FDA-approved for the treatment of gait deficits in adult patients with multiple sclerosis, utilizes translingual neurostimulation to stimulate trigeminal and facial nerves via the tongue, aiming to induce neuroplastic changes. While there are early, promising data for PoNS treatment to improve gait and balance in multiple sclerosis, stroke, and traumatic brain injury, no pre-clinical or clinical studies have been performed in ALS. Although reasonably safe, high costs and prescription requirements will limit PoNS accessibility. At this time, due to the lack of ALS-relevant data, we cannot endorse the use of PoNS as an ALS treatment.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
